JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Listă Acțiuni・Becton Dickinson and Co

Becton Dickinson and Co

Închisă

SectorSănătate

144.15 -1.48

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

142.93

Maxim

146.3

Indicatori cheie
By Trading Economics
Venit	-1.3B 382M
Vânzări	-639M 5.3B
P/E Medie Sector	24.546 67.147
EPS	2.91
Randament dividend	2.74
Marjă de profit	7.273
Angajați	70,000
EBITDA	-86M 1.2B

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+23.42% upside

Dividende
By Dow Jones
Randament dividend Medie Sector	2.74% 2.36%
Următoarele câștiguri	7 mai 2026
Data viitoare de dividende	30 iun. 2026
Următoarea dată ex-dividende	9 iun. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-15B 43B
Deschiderea anterioară	145.63
Închiderea anterioară	144.15

Sentimentul știrilor

By Acuity

25%

75%

72 / 347 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

167 / 206.99 Suport & Rezistență

Becton Dickinson and Co Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

7 aug. 2025, 11:19 UTC

Câștiguri

Becton Dickinson Boosts Outlook as 3Q Results Beat Estimates

14 iul. 2025, 14:26 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal -- 2nd Update

14 iul. 2025, 11:08 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal -- Update

14 iul. 2025, 10:37 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal

7 aug. 2025, 10:32 UTC

Câștiguri

Becton Dickinson Expects to Complete Remaining $250M of $1B Share-Buyback Commitment by End FY25 >BDX

7 aug. 2025, 10:31 UTC

Câștiguri

Becton Dickinson Backs FY25 View of Rev $21.8B-$21.9B >BDX

7 aug. 2025, 10:31 UTC

Câștiguri

Becton Dickinson Had Seen FY25 Adjusted EPS $14.06-$14.34 >BDX

7 aug. 2025, 10:30 UTC

Câștiguri

Becton Dickinson Raises FY25 View To Adj EPS $14.30-Adj EPS $14.45 >BDX

7 aug. 2025, 10:30 UTC

Câștiguri

Becton Dickinson 3Q Adj EPS $3.68 >BDX

7 aug. 2025, 10:30 UTC

Câștiguri

Becton Dickinson 3Q Net $574M >BDX

7 aug. 2025, 10:30 UTC

Câștiguri

Becton Dickinson 3Q Rev $5.51B >BDX

7 aug. 2025, 10:30 UTC

Câștiguri

Becton Dickinson 3Q EPS $2.00 >BDX

15 iul. 2025, 18:32 UTC

Achiziții, Fuziuni, Preluări

Waters Corp. Deal for Becton Dickinson Unit a Long-Term Play With Some Risks -- Analysis

15 iul. 2025, 18:31 UTC

Achiziții, Fuziuni, Preluări

Waters Deal for Becton Unit Pairs Near-Term Risks With Possible Long-Term Rewards, Analysts Say

14 iul. 2025, 16:12 UTC

Market Talk

Achiziții, Fuziuni, Preluări

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

14 iul. 2025, 15:06 UTC

Achiziții, Fuziuni, Preluări

Waters Stock Is Falling on Deal to Combine With Becton Dickinson Unit -- Barrons.com

14 iul. 2025, 14:11 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5B Deal -- 2nd Update

14 iul. 2025, 10:53 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal -- Update

14 iul. 2025, 10:22 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson Unit to Combine With Waters Corp. in $17.5B Deal

14 iul. 2025, 10:22 UTC

Achiziții, Fuziuni, Preluări

Waters To Assume About $4 Billion Incremental Debt >WAT BDX

14 iul. 2025, 10:22 UTC

Achiziții, Fuziuni, Preluări

Becton Dickinson to Get $4 Billion Cash Distribution Prior to Closing >WAT BDX

14 iul. 2025, 10:21 UTC

Achiziții, Fuziuni, Preluări

Waters Holders to Own 60.8% of Combined Company, Becton Dickinson Holders to Own 39.2% >WAT BDX

14 iul. 2025, 10:20 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson: Combined Company to Have About $9 Billion Revenue, $3.3 Billion Adjusted Ebitda >WAT

14 iul. 2025, 10:19 UTC

Achiziții, Fuziuni, Preluări

Correct: Waters, Becton Dickinson See About $290 Million Revenue Synergies by Year Five >WAT BDX

14 iul. 2025, 10:19 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson See About $345 Million Annualized Ebitda Synergies by 2030 >WAT BDX

14 iul. 2025, 10:18 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson See About $290 Revenue Cost Synergies by Year Five >WAT BDX

14 iul. 2025, 10:18 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson See About $200 Million Cost Synergies by Year Three >WAT BDX

14 iul. 2025, 10:17 UTC

Achiziții, Fuziuni, Preluări

Waters: Becton Dickinson Deal Doubles Total Addressable Market to About $40 Billion >WAT

14 iul. 2025, 10:16 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson Deal Structured as Reverse Morris Trust >WAT BDX

14 iul. 2025, 10:16 UTC

Achiziții, Fuziuni, Preluări

Waters, Becton Dickinson Deal Valued at About $17.5 Billion >WAT BDX

Comparație

Modificare preț

Becton Dickinson and Co Așteptări

Obiectiv de preț

By TipRanks

23.42% sus

Prognoză pe 12 luni

Medie 180.58 USD 23.42%

Maxim 221 USD

Minim 157 USD

În baza a 12 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBecton Dickinson and Co - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

12 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 12 analiști care au acordat evaluări ale acțiunilor Becton Dickinson and Co - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

167 / 206.99Suport & Rezistență

Bearish events outweigh bullish events.

There is one bearish event.

Sentiment

By Acuity

72 / 347 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Becton Dickinson and Co

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.